News | Stents Drug Eluting

OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 2 in Denver. The results provide fresh insights into the optimal treatment of patients with acute coronary syndrome (ACS) using the COMBO Dual Therapy Stent.

Home November 01, 2017
Home
News | Stents Bifurcation

The double kissing (DK) crush two-stent technique was associated with a lower rate of target lesion failure at one year compared with provisional stenting (PS) in the treatment of true distal bifurcation lesions of the left main artery, according to a large-scale randomized trial.

Home November 01, 2017
Home
News | Cardiac Diagnostics

Analytics 4 Life announced it will be presenting new clinical data on the company's ongoing Coronary Artery Disease Learning and Algorithm Development (CADLAD) study at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 scientific symposium, Oct. 29-Nov. 2 in Denver.

Home November 01, 2017
Home
News | Radiation Dose Management

James A. Brink, M.D., FACR, chair of the American College of Radiology (ACR) Board of Chancellors, met with the House Committee on Science, Space and Technology Subcommittee on Energy to urge more research on low-dose medical radiation effects to inform future safety practices. He also told the Committee that medical imaging and radiation oncology save lives.

Home November 01, 2017
Home
News | Heart Valve Technology

Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.

Home November 01, 2017
Home
News | Cath Lab

November 1, 2017 โ€” Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strategy ...

Home November 01, 2017
Home
News | Embolic Protection Devices

October 31, 2017 โ€” The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the ...

Home October 31, 2017
Home
News | Heart Valve Technology

Edwards Lifesciences Corp. announced new data demonstrating substantial economic advantages of the Edwards Sapien 3 transcatheter aortic heart valve for patients suffering from severe, symptomatic aortic stenosis (AS) who are at intermediate risk for open-heart surgery. Results of the economic analysis, which is the first-of-its-kind report on intermediate-risk patients, were presented as a late-breaking clinical trial at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Oct. 29-Nov. 2 in Denver.

Home October 31, 2017
Home
News | Stents Bioresorbable

Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular scaffold (BVS) trial to date, found BVS to be noninferior to a cobalt-chromium everolimus-eluting stent (CoCr-EES) for target lesion failure (TLF).

Home October 31, 2017
Home
News | Stents Bioresorbable

October 31, 2017 โ€” The U.S. Food and Drug Administration (FDA) issued a warning to healthcare providers that interim ...

Home October 31, 2017
Home
News | Cath Lab

October 30, 2017 โ€” New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left main ...

Home October 30, 2017
Home
News | EP Lab

The American College of Cardiology, along with the American Heart Association and the Heart Rhythm Society, published new guidelines for the treatment of patients with ventricular arrhythmias and the prevention of sudden cardiac death.

Home October 30, 2017
Home
News | Heart Failure

October 30, 2017 โ€” Researchers have discovered a previously unrecognized healing capacity of the heart. In a mouse model ...

Home October 30, 2017
Home
News

Micro Interventional Devices Inc. (MID) recently announced the second successful implantation of its MIA (Minimally Invasive Annuloplasty) technology. The patient was enrolled in the first arm of the STTAR (Study of Transcatheter Tricuspid Annular Repair) clinical trial studying the safety and efficacy of MID's MIA device designed to eliminate or greatly reduce tricuspid regurgitation.

Home October 30, 2017
Home
News | Medical 3-D Printing

Entering their pre-market phase of development, Materialise is working with select U.S. and EU hospital partners to validate the importance of accurate 3-D modeling to help physicians plan complex transcatheter mitral valve replacement and repair (TMVR/r) procedures.

Home October 30, 2017
Home
Subscribe Now